RxDoctor Payments Data

Caroline Marzbani, MD

Cardiovascular Disease · Houston, TXNPI 1932540143

Payments from drug & device makers

$3,357in general payments, 2019–2025

Across 47 payments — averaging $71.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$1K
  • Angiodynamics, Inc.$121
  • Amgen$91
  • Novartis$36
  • Pfizer$32
  • plus $29 from 1 others

What the payments were for

  • Travel & lodging$89727%
  • Food & beverage$2,45973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott31$1,954
Medtronic(2 entities)3$1,093
Angiodynamics, Inc.1$121
Amgen6$91
Novartis2$36
Pfizer2$32
Cardiovascular Systems Inc.2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,357 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$7,492
Medicare patients
33
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis21$548,028
EliquisApixaban340$302,638
EntrestoSacubitril/Valsartan282$255,977
FarxigaDapagliflozin Propanediol183$148,534
XareltoRivaroxaban80$68,113
Repatha SureclickEvolocumab56$45,606
Repatha SyringeEvolocumab28$25,041
VascepaIcosapent Ethyl48$21,589
Rosuvastatin Calcium434$18,726
BrilintaTicagrelor16$16,577
JardianceEmpagliflozin27$15,889
Atorvastatin Calcium444$13,174
Praluent PenAlirocumab24$11,913
Potassium Chloride157$11,037
Amiodarone Hcl131$8,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$32$850,665361 claims
NovartisEntresto$36$255,977282 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →